Instrumento Inactivo

Otros idiomas Blue Water Ventures International, Inc. Other OTC

Acciones

BWVI

US09609E1055

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	12/12
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	12/12
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding	26/09/23
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder	13/07/23
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones	21/04/23
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review	13/04/23
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab	29/03/23
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	21/03/23
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD	21/03/23
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD	21/03/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	15/02/23
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	02/02/23
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD	02/02/23
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	26/01/23
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD	26/01/23
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	10/01/23
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer	10/01/23
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director	29/11/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Blue Water Ventures International, Inc. Other OTC

Acciones

BWVI

US09609E1055

Otros idiomas

Filtros